Also known as tezepelumab and TEZSPIRE.
Phase 3 CROSSING found TEZSPIRE produced sustained histologic remission, reduced dysphagia scores and achieved endoscopic remission through week 52 in adolescents and adults with eosinophilic esophagitis.
